When it completes its $5.3 billion acquisition of Waltham-based Alere later this year, Abbott Laboratories will be getting one of the world’s largest makers of point-of-care diagnostic tests, a fast-growing sector.
Thanks to antitrust rules, though, Abbott will be taking on a slimmed-down version of Alere by the end of September.
